Aging & Elder Health Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Aging & Elder Health Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer Institute, Hollywood
New research in the area of breast cancer detailed
April 10th, 2005
Investigators in the United States and Japan have published new breast cancer data. Study 1: Study results suggest that use of fulvestrant earlier in the treatment strategy for heavily pretreated postmenopausal women with breast cancer may yield more effective response. "Fulvestrant (Faslodex) is a new estrogen receptor (ER) antagonist that has no agonist effects. It binds, blocks, and accelerates degradation of the ER, leading to a complete abrogation of estrogen-sensitive gene transcription. In postmenopausal women with advanced breast cancer progressing on prior endocrine therapy, fulvestrant is at least as effective as the third-generation...
Source: Aging & Elder Health Week (2005-04-10)
|
